RSS Alerts

Share

More services

Related Stories

  • Proceedings of the 2nd Annual London Genetics Pharmacogenetics conference 2010 Pharmacogenetics: Why, How and When?
    The importance of pharmacogenetics and stratified medicine as part of the drug development processes is now widely acknowledge, offering the opportunity to address many of the challenges facing the biopharmaceutical industry today and supporting an era where cost-effectiveness and value-based pricing rule. Moving on from the inaugural London Genetics Pharmacogenetic conference in 2009, at which the role of pharmacogenetics in drug discovery and development was debated, the 2nd London Genetics conference, entitled ‘Pharmacogenetics – Why, How and When?’ focused on how and when to apply stratified approaches from drug discovery through to cost-effectiveness evaluation and reimbursement.
  • Therapeutic peptides – a revival of interest
    The innovation process in the pharmaceutical industry is, as for all evolutionary models of technological change, both ‘pushed by technology’ and ‘demand driven’. The core of the innovation relies on the research for new high value-added drugs to address unmet medical needs. To this end, tens of billions of dollars are invested per year in R&D. However, the decreasing number of approved drugs, which is accompanied by increasing R&D expenditures, demands alternative approaches to increase R&D productivity. This situation contributes to a revival of interest in peptides as potential tools and drug candidates.
  • Drug Delivery – enabling technology for drug discovery and development
    Although drug delivery may not attract the attention and press coverage of some of the other disciplines involved in drug discovery, it is equally important in the development of a successful product. Effective drug delivery can be the difference between getting a molecule into clinical trial rather than a chemical sitting in a brown bottle on the shelf, or a forgotten compound languishing in a 96 well storage plate. It can mean the difference between a drug that just wipes its feet in the market and the discovery of a blockbuster.
  • AstraZeneca and Nektar sign worldwide agreement for Nektar drug development programmes to address opioid-induced constipation
    AstraZeneca and Nektar Therapeutics announced recently that they have entered into a worldwide license agreement for two drug development programmes: NKTR-118, a late-stage investigational product being evaluated for the treatment of opioid-induced constipation, and the NKTR-119 programme, an early-stage programme that is intended to deliver products for the treatment of pain without constipation side-effects.
  • Together we will beat cancer
    Despite the doom and gloom surrounding the pharmaceutical industry and the many commentaries highlighting inefficiencies of the sectors operating model, 2011 has proven to be a near-record year for approvals of innovative new drugs. These approvals include seven new cancer treatments with two of these (Pfizer’s crizotinib, Xalkori™ and Roche’s vemurafenib, Zelboraf™) made in conjunction with companion genetic tests, reinforcing the notion that the practice of stratified medicine has truly arrived. The forthcoming special issue of Drug Discovery Today on cancer highlights innovative contributions in basic, translational and clinical research made by UK scientists and clinicians in the fight against cancer.

Top 5 Stories

News

Competition intensifying for transdermal pain products

12 March 2010

The convergence of active lifestyles, aging joints and a more enlightened approach by practitioners to treating pain is contributing to an attractive demand picture for pain management drug products.

This favourable outlook has led to an increase in the number of participants competing for a share of the market. Because of the ability of transdermal formulations to deliver pain medication consistently and unobtrusively with minimal side-effects, a range of companies are pursuing the transdermal route for a number of generic analgesics.

This increased level of competition is taking a toll on the margins of existing players. There were three approved fentanyl patches on the US market in 2006. With the loss of patent protection for J&J’s Duragesic fentanyl brand, that number rose to seven by 2009. During this time, the dollar value of Duragesic sales in North America fell by almost fifty percent.

In Europe, the market is even more intense: there are a dozen marketed transdermal fentanyl products competing for market share. For mild to moderate pain, oral pain management drugs in Europe are coming under pressure from several brands of buprenorphine patches and diclofenac patches and gels that are marketed in the region.

And then there are the pipeline candidates. Transdermal versions of a number of analgesics, some powerful and exotic, are being developed in transdermal form – a group that includes bupivacaine, ketoprofen and dexamethasone.

Several of these development programs involve international partnerships designed to take advantage of perceived opportunities in regional markets.

An important demographic demand driver is the aging population in developed economies, which is expected to lead to considerable increases in several conditions for which pain management will be crucial to quality of life. One example is osteoarthritis, an often painful condition in which oral medications compete with topical pain relief formulations. Volteren and Felbinac (Japan) are important competitors in this segment.

A recent analysis of the global transdermal pain management segment by Greystone Associates includes an assessment of factors influencing demand for transdermal pain management products and forecasts for the growth of transdermal pain management products by drug class, region and technology. For more information, please see the Greystone Associates website.

 

This article is featured in:
Regulatory

 

Comment on this article

You must be registered and logged in to leave a comment about this article.

Copyright © 2012
Elsevier Ltd. All rights reserved.
Terms & Conditions | Privacy | Website Design Working with water